Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Silvia Hofer; Katarzyna Elandt; Richard Greil; Andreas F Hottinger; Urs Huber; Dieter Lemke; Christine Marosi; Adrian Ochsenbein; Josef Pichler; Ulrich Roelcke; Patrik Weder; Thilo Zander; Wolfgang Wick; Michael Weller

doi:10.3109/0284186X.2011.572913

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

Silvia Hofer, Katarzyna Elandt, Richard Greil (Co-author), Andreas F Hottinger, Urs Huber, Dieter Lemke, Christine Marosi, Adrian Ochsenbein, Josef Pichler, Ulrich Roelcke, Patrik Weder, Thilo Zander, Wolfgang Wick, Michael Weller

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

35 Citations (Web of Science)

Original language	English
Pages (from-to)	630-635
Journal	ACTA ONCOLOGICA
Volume	50
Issue number	5
DOIs	https://doi.org/10.3109/0284186X.2011.572913
Publication status	Published - 2011

Keywords

PHASE-II TRIAL
PLUS IRINOTECAN
ADJUVANT TEMOZOLOMIDE
MALIGNANT GLIOMAS
GLIOBLASTOMA
RADIOTHERAPY
PROGRESSION
CONCOMITANT
SURVIVAL

Access to Document

10.3109/0284186X.2011.572913

Cite this

Hofer, S., Elandt, K., Greil, R., Hottinger, A. F., Huber, U., Lemke, D., Marosi, C., Ochsenbein, A., Pichler, J., Roelcke, U., Weder, P., Zander, T., Wick, W., & Weller, M. (2011). Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. ACTA ONCOLOGICA , 50(5), 630-635. https://doi.org/10.3109/0284186X.2011.572913

Hofer, Silvia ; Elandt, Katarzyna ; Greil, Richard et al. / Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. In: ACTA ONCOLOGICA 2011 ; Vol. 50, No. 5. pp. 630-635.

@article{02cf80ddd5644819a79aabd29e846739,

title = "Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.",

keywords = "PHASE-II TRIAL, PLUS IRINOTECAN, ADJUVANT TEMOZOLOMIDE, MALIGNANT GLIOMAS, GLIOBLASTOMA, RADIOTHERAPY, PROGRESSION, CONCOMITANT, SURVIVAL",

author = "Silvia Hofer and Katarzyna Elandt and Richard Greil and Hottinger, {Andreas F} and Urs Huber and Dieter Lemke and Christine Marosi and Adrian Ochsenbein and Josef Pichler and Ulrich Roelcke and Patrik Weder and Thilo Zander and Wolfgang Wick and Michael Weller",

note = "Third Medical Department at the Private Medical University Hospital Salzburg, Austria",

year = "2011",

doi = "10.3109/0284186X.2011.572913",

language = "English",

volume = "50",

pages = "630--635",

journal = "ACTA ONCOLOGICA ",

issn = "0284-186X",

number = "5",

}

Hofer, S, Elandt, K, Greil, R, Hottinger, AF, Huber, U, Lemke, D, Marosi, C, Ochsenbein, A, Pichler, J, Roelcke, U, Weder, P, Zander, T, Wick, W & Weller, M 2011, 'Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.', ACTA ONCOLOGICA , vol. 50, no. 5, pp. 630-635. https://doi.org/10.3109/0284186X.2011.572913

Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. / Hofer, Silvia; Elandt, Katarzyna; Greil, Richard (Co-author) et al.
In: ACTA ONCOLOGICA , Vol. 50, No. 5, 2011, p. 630-635.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials.

AU - Hofer, Silvia

AU - Elandt, Katarzyna

AU - Greil, Richard

AU - Hottinger, Andreas F

AU - Huber, Urs

AU - Lemke, Dieter

AU - Marosi, Christine

AU - Ochsenbein, Adrian

AU - Pichler, Josef

AU - Roelcke, Ulrich

AU - Weder, Patrik

AU - Zander, Thilo

AU - Wick, Wolfgang

AU - Weller, Michael

N1 - Third Medical Department at the Private Medical University Hospital Salzburg, Austria

PY - 2011

Y1 - 2011

KW - PHASE-II TRIAL

KW - PLUS IRINOTECAN

KW - ADJUVANT TEMOZOLOMIDE

KW - MALIGNANT GLIOMAS

KW - GLIOBLASTOMA

KW - RADIOTHERAPY

KW - PROGRESSION

KW - CONCOMITANT

KW - SURVIVAL

U2 - 10.3109/0284186X.2011.572913

DO - 10.3109/0284186X.2011.572913

M3 - Original Article

C2 - 21495907

SN - 0284-186X

VL - 50

SP - 630

EP - 635

JO - ACTA ONCOLOGICA

JF - ACTA ONCOLOGICA

IS - 5

ER -

Hofer S, Elandt K, Greil R, Hottinger AF, Huber U, Lemke D et al. Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials. ACTA ONCOLOGICA . 2011;50(5):630-635. doi: 10.3109/0284186X.2011.572913